Both hepatitis B virus (HBV) and hepatitis C virus (HCV) are important worldwide problems. It is believed that 300 million people have been exposed to hepatitis B.' In Europe, based on a carrier rate in blood donors of 0 O/% and a population of 400 million, it is estimated that four million have been exposed to hepatitis C. Hepatocellular cancer is estimated to have an incidence of between 250 000 and 1-2 million per year worldwide.2 It is the seventh commonest cause of cancer in men, and most show evidence of HBV or HCV infection.
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The relation of the virus to the development of hepatocellular carcinoma (HCC) is through chronic hepatitis and cirrhosis (Fig 1) . Almost all patients with virus related HCC have an underlying cirrhosis. The hepatocyte necrosis and mitosis of chronic hepatitis favour nodular regeneration which, in appropriate circumstances, is followed by hepatocyte dysplasia and carcinoma.3 Although nodular regeneration and cirrhosis remain the most important antecedents, the tumour can develop in the absence of cirrhosis. In this case, and by analogy with the HBV-like woodchuck chronic hepatitis, necroinflammatory activity may be an important requisite. Carcinogenesis is a multistage process in which both virus and host play a part.5 The essential end result is the disorganisation and rearrangement of hepatocyte DNA (Fig 2) . The molecular mechanism for the postulated hepatocarcinogenic role of HBV is not known. During the course of HBV, the virus becomes integrated with host chromosomal DNA but the method by which this leads to cancer is uncertain. Integration is accompanied by chromosomal deletions and translocations, which effect cell growth and differentiation (insertional mutagenesis). The deletions are not related to the sides of integration, however, and in 15% of cancers, integrated sequences are not found in the tumour.5 In the human HCC, the semirandom integration of HBV DNA into the host genome has not been associated with the overexpression of a particular proto-oncogene or with deletion of a specific region of the genome harbouring a potential anti-oncogene. 6 No consistent pattern of integration has emerged and the viral genome may integrate in different sites in tumours from different subjects.
The hepatitis B X antigen (HBX) has been suggested as a transactivator increasing the rate of transcription of oncogenes. 7 8 The pre-S HBV envelope protein may accumulate in toxic amounts sufficient for carcinogenesis. Thus in transgenic mice, overproduction of HBV pre-S, results in severe hepatic inflammation and regeneration, which is followed by neoplasia. Transforming growth factor ot may be a cofactor in some cases. It is expressed at a high value in 80% of human HCC.12 Histochemistry shows that it is localised with HBsAg to the same hepatocyte but not in the cancer cell.
Chronic hepatitis, progressing to cirrhosis, remains the most important precancerous aetiological factor. HBV induces the cancer through integration, transactivation, mutations in tumour suppressor genes and increases in transforming growth factor a.
Hepatitis C virus
The most serious complication of HCV disease is the development of hepatocellular cancer. There are geographical differences in the aetiological importance of HCV in HCC. The association seems to be strongest in carriers where the prevalence of HBV is low, for instance, Europe or Japan. Economics play a part in planning screening programmes. In Japan, such procedures as ultrasound and a fetoprotein estimations are routinely available at no cost to the patient. This is clearly not so in most other parts of the world. The prognosis for HCC is so poor that where cost is an important consideration, there is probably a reluctance to screen. After local treatment, such as resection, the cirrhosis persists. This is a pre-neoplastic state, so that HCC may arise in cirrhotic nodules one after another.36 Transplantation may be an option in early cases, but donor livers are never likely to be in adequate supply. There is no firm consensus that screening reduces the death rate of HCC.
Management
Accurate localisation is essential, particularly if surgery is planned. This is best done by computed tomography with or without angiography. It may be combined with iodised oil (lipiodol), which has an avidity for HCC and which is injected into the hepatic artery; abdominal computed tomography is performed two weeks later. The lipiodol is taken up by the tumour or tumours and 96% are detected.37 The procedure, however, does add to the complexity of the diagnosis and is not always necessary. Serum markers for HBV and HCV are performed, but there is little difference in management whether or not these are positive and the HCC is virus related.
Successful local resection of the tumour depends on size (less than 5 cm in diameter), position, particularly in relation to large vessels, presence of satellite lesions, and of a capsule and of a number of lesions (Table II) .
It also depends on the age and general condition of the patient, the grade of hepatic decompensation (Child's grade) and the presence of extrahepatic metastases. Improved results for resection have followed better knowledge of the segmental anatomy of the liver and hence better localisation of the tumour. Also this has followed the use of intraoperative diagnostic ultrasound.38 In Spain, survival increased from 12-4 months in untreated controls to 27 Tumour obliteration may be attempted locally. In general, those selected tend to be unsuitable for resection or transplantation and hence are poorer risks and consequently the results are worse.
Using ultrasound guidance, absolute alcohol may be introduced directly into the tumour.45 It is especially useful for tumours less than 3 cm in diameter. The one year survival for Child's A and B grades is 87% and at two years it is 70%.46 The alcohol injections are repeated two to three times a week until the tumour is obliterated. The objective of injections may be palliative or an attempt to cure.47 Results of 98 Japanese patients, where the ethanol injection was to cure showed necrosis of the tumour, reduction in ac fetoprotein, and improved arteriographic appearances.47 One, two, three, four, and five year survival rates were 85%, 70%/, 62%, 52%, and 52%, and the one, two, three, four, and five year recurrence rate was 26%, 28%, 5/1%, 60%, and 60%.
The recurrences usually resulted from new lesions in different parts of the liver. Other local procedures include ultrasound guided cryosurgery.48 49 Chemoembolisation via the hepatic artery may be performed using lipiodol tagged with doxyrubicin or 1131 iodine.50 Results 
